These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 26087971)

  • 1. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
    Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
    Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.
    Noe A; de Bruijn RE; Blank C; Horenblas S; Haanen J; Bex A
    World J Urol; 2016 Aug; 34(8):1067-72. PubMed ID: 26832350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Sharma P; Zargar-Shoshtari K; Caracciolo JT; Fishman M; Poch MA; Pow-Sang J; Sexton WJ; Spiess PE
    Urol Oncol; 2015 Aug; 33(8):339.e17-23. PubMed ID: 26094169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
    de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
    Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.
    Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
    Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
    Bozkurt O; Inanc M; Hacibekıroglu I; Esbah O; Seker M; Ulas A; Aydin K; Uysal M; Kücüköner M; Uncu D; Cıltas A; Unal OÜ; Durnali A; Demırcı U; Berk V; Tonyali O; Oksüzoglu B; Karaca H; Ozkan M
    Anticancer Res; 2014 Aug; 34(8):4463-70. PubMed ID: 25075086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
    Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
    Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
    Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
    World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
    Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
    Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.
    de Bruijn RE; Nijkamp J; Noe A; Horenblas S; Haanen JB; Prevoo W; Bex A
    Urol Oncol; 2016 Jun; 34(6):258.e7-258.e13. PubMed ID: 26822077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
    Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
    Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?
    Culp SH; Tannir NM; Abel EJ; Margulis V; Tamboli P; Matin SF; Wood CG
    Cancer; 2010 Jul; 116(14):3378-88. PubMed ID: 20564061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.